Inflammatory diseases on the research agenda for 2025?
Experts in nonclinical disease models
For 25 years, the members of IPST’s team called themselves “Discovery & Lead Optimization Scientists”.
Working across a global pipeline of preclinical leads as immense as it is varied, IPST eschews business labelling: Cardiovascular specialists? Yes. But also “Inflammatory disease specialists”. And “Respiratory disease specialists”. Oh, and “Hematology disease specialists”, too.
In a creative and collaborative environment such as drug development, it helps to avoid the confinement of knowledge; We aim to achieve the full power of collaboration through complementary expertise, and combined imagination.
Contact us to see how we can leverage the combined experience and passion of our respective teams.
Dedicated to scientific excellence since 1999, IPS Therapeutique (IPST) specializes in the preclinical evaluation of the efficacy and safety of new drugs using validated and highly predictive models.
Investigative-toxicology-V2
Reduce your costs of early drug development
De-risking pre-clinical drug candidates for scientists has been the focus of IPS Therapeutique (IPST) for 25 years; every in vivo model has been developed with this dual purpose in mind: confirm and define the conditions for efficacy, and identify early indicators of toxicity.
From proteomics to GLP-compliant safety pharmacology studies, IPST’s scientists understand the impact of attrition on drug discovery and use early detection of failure signals to lower the cost of pre-clinical development.
